Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study
source: The Pediatric Infectious Disease Journal
year: 2017
authors: Sirima SB, Tiono A, Gansané Z, Siribié M, Zongo A, Ouédraogo A, François N, Strezova A, Dobbelaere K, Borys D.
summary/abstract:BACKGROUND:
Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) were evaluated in children with sickle cell disease (SCD), who are at increased risk for infections.
METHODS:
In this phase III, open-label, single-center, controlled study in Burkina Faso (NCT01175083), children with SCD (S) or without SCD (NS) were assigned to 6 groups (N = 300): children 8-11 weeks of age ( RESULTS:
One month postprimary vaccination, for each vaccine serotype ≥98% of infants in the CONCLUSIONS:
PHiD-CV was immunogenic with an acceptable safety profile in children with and without SCD starting vaccination at 8 weeks to 23 months of age.
DOI: 10.1097/INF.0000000000001518
read more full text
Related Content
-
FDA Clears Graphite Bio to Begin Trial for Gene Therapy in Sickle Cell DiseaseIn response to Graphite Bio’s investig...
-
More Cures for More Patients Through Sickle Cell Research: Courtney Fitzhugh, MDhttps://www.youtube.com/watch?v=OvdpT1Dn...
-
CIRM and NHLBI Collaborating to Fund Cell and Gene Therapies for Sickle Cell DiseaseThe California Institute for Regenerativ...
-
Sickle Cell Treatment Endari Now Available in the United StatesEmmaus Life Sciences has announced that ...
-
FDA Awards UNC Researcher $2M Grant to Study Kidney Disease in Sickle Cell AnemiaThe U.S. Food and Drug Administration (F...
-
Blood transfusions for treating acute chest syndrome in people with sickle cell diseaseBackground: Sickle cell disease is an...
-
Gene Therapy for Blood DisordersIn the context of intense scrutiny over ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.